Lineage Cell Therapeutics

LCTX • NYSE •
Overview Stats Financials News

Quarterly Financials

Values in thousands 2023-12-31 2023-09-30 2023-06-30 2023-03-31
Revenue $2,088 $1,246 $3,225 $2,386
Gross Profit 1,657 1,077 3,098 2,267
EBITDA -6,187 -6,469 -4,704 -6,512
EBIT -6,362 -6,645 -4,874 -6,642
Net Income -4,775 -7,110 -5,229 -4,404
Net Change In Cash 2,088 1,246 3,225 2,386
Cost of Revenue 18,519 4,185
Free Cash Flow -6,110 -5,176 -6,524 -11,430
Cash 35,442 31,474 33,886 15,451
Basic Shares 172,663 174,868 170,592 170,127

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue $8,945 $14,703 $3,896 $773
Gross Profit 7,582 13,975 2,470 388
EBITDA -24,041 -19,824 -52,791 -25,012
EBIT -24,733 -22,520 -49,211 -26,447
Net Income -21,486 -26,353 -38,564 -20,685
Net Change In Cash 8,945 14,703 3,896 773
Cost of Revenue -43,468 23,114 23,150
Free Cash Flow -29,240 646 -23,915 -19,817
Cash 35,442 11,355 55,742 32,585
Basic Shares 172,663 169,792 164,502 150,044

Earnings Calls

Quarter EPS
2023-12-31 -$0.03
2023-09-30 -$0.04
2023-06-30 -$0.03
2023-03-31 -$0.03